Navigation Links
No drop in IQ seen after bypass for child heart surgery
Date:11/10/2008

The use of cardiopulmonary bypass does not cause short-term neurological problems in children and teenagers after surgery for less complex heart defects, according to pediatric researchers. The new finding contrasts favorably with previous studies that showed adverse neurological effects after newborn surgery for more complex heart conditions.

"This is good news for school-aged children who receive surgery for these less complex heart defects," said study leader Michael D. Quartermain, M.D., a pediatric cardiologist at The Children's Hospital of Philadelphia. Quartermain presented the study group's results at the American Heart Association's Scientific Sessions today in New Orleans.

The research, conducted at the Cardiac Center of Children's Hospital, studied 41 patients, aged five to 18, who underwent heart surgery at the hospital while a heart-lung machine circulated their blood (under cardiopulmonary bypass, or CPB). All the patients had milder forms of congenital heart disease usually characterized by an abnormal heart valve or by a hole between the heart's chambers.

Such defects, while present from birth, are often not detected until a patient is school age or even older. Patients do not show obvious symptoms and are otherwise healthy, but surgical intervention is often recommended to prevent complications later in life. In contrast, more complex congenital heart defects, such as hypoplastic left heart syndrome, a severely underdeveloped ventricle, are life-threatening in infancy, and require urgent surgical repair.

Previous studies of survivors of more complex heart surgery have found neurological problems, such as impaired motor development, lower I.Q. scores and reduced language skills. As medical regimens and surgical techniques have advanced, more recent studies have found milder neurological problems or normal neurological outcomes, but long-term outcomes remain a concern. Likewise, adults with acquired heart disea
'/>"/>

Contact: John Ascenzi
Ascenzi@email.chop.edu
267-426-6055
Children's Hospital of Philadelphia
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Hispanics less likely to have repeat revascularizations 1 year after angioplasty
2. Banned Obesity Drug Tied to Heart Risks Long After Use
3. More People Living Longer After Cancer Diagnosis
4. How women can improve their quality of life after breast cancer treatment
5. Sudden Death Risk Highest 30 Days After Heart Attack
6. Cone-beam CT: Just as useful as MDCT before and after percutaneous vertebroplasty
7. Treating Osteoporosis After Hip Fracture
8. Beware of Ten Mistakes after Social Security Denies Disability Benefits
9. Promoting the healing process after a heart attack
10. New National Patient and Surgeon Surveys Show Post-Surgical Care Critical to Optimal Weight Loss After Bariatric Surgery
11. Informed-Choice Reinforces Need to Test Supplements for Inadvertent Contamination After Recent NFL Players Positive Tests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2009)...ngsters with the disease , , THURSDAY, J...betes are more likely to be overweight than those ...ous health complications, researchers say. , Th...weight problems faced by U.S. youngsters with type...t usually shows up in childhood or in young adults...
(Date:7/2/2009)...itis B virus (HBV) are associated with the develop...tients with HBV infections are at increased risk o...in the Journal of the National Cancer Institute ,...nown cause of hepatocellular carcinoma (HCC), the ... have looked at whether patients with specific mut...
(Date:7/2/2009)...y night saw the launch of (RED)ZONES at the first ...d off their new tour to a rapturous sold out crowd...tion areas directly adjacent to the stage which wi... for the (RED)ZONES are available through auction ...to the Global Fund to help fund AIDS programs in A...
(Date:7/2/2009)...hytherapy and remain free of disease for five year...10 years, according to a study in the July 1 issue...gy*Biology*Physics , the official journal of the A...Brachytherapy is the placement of radioactive sour...or temporarily, depending upon the cancer. , In t...
Breaking Medicine News(10 mins):Health News:Kids With Type 1 Diabetes Often Overweight 2Health News:(RED)ZONES Launch at First U2 360 Degrees Concert in Barcelona 2Health News:(RED)ZONES Launch at First U2 360 Degrees Concert in Barcelona 3
...e WHO has issue a checklist for doctors and nurse ...s. Basic mistakes like not washing hands by the h...arters. The WHOs 9 solution is meant to improve p...essen the number of health care related accidents ...
...e Delhi High Court Wednesday held that the misuse ...taff would be viewed seriously, stressing that th...ision bench of Justice T.S. Thakur and Justice S.N... of the hospitals of both state and central govern...
...California-based Keralite doctor has bagged this y...the National Ethnic Coalition of Organisations (NE... award May 12, said he was "really delighted". "Th...o be a boost for all my future endeavours," Eapen ...
...ldiers returning from Iraq who have migraine heada...mptoms of post-traumatic stress, depression or anx...ording to research. The study involved 3,621 Unite...en a health screening questionnaire within 90 days...
Other Medicine News:Health News:UN Agencys Checklist on Health Care Error 2Health News:Migraines may Be a Symptom of Other Problems for Iraq Soldiers 2
(Date:6/25/2009)...OX(R) and EMBEDA (TM) Data Highlighted at the Coll..., , RENO, Nev., June 25 King ...d that the Company is presenting safety and effica...wo novel opioid analgesic formulations that are in...llege on Problems of Drug Dependence. King is als...
(Date:6/24/2009)...LEUVEN, Belgium, June 25 ..., Lead Product for the,Non-Surgical Treatment of ... ThromboGenics NV (Euronext Brussels: THR), a bio...evelopment of innovative treatments for eye,disea...hat its lead product,microplasmin, which is in Ph...
(Date:6/24/2009)...iminary top-line results of second Phase III study...igue and improved daily function in fibromyalgia p...II study , , PALO ALTO, Calif., and BRUSSELS, J...egulated information -- Jazz Pharmaceuticals, Inc...B) announced today positive preliminary top-line r...
(Date:6/24/2009)...TLE, June 24 A Common... Cooperative is structured with incentives align... ways that make the most sense operationally and c...rofiles looking at medical systems that have the a...necessary for a high performing health care system...
Breaking Medicine Technology:King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 2King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 3King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 4King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 5King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 6ThromboGenics' Microplasmin Phase III Program Progressing According to Schedule 2ThromboGenics' Microplasmin Phase III Program Progressing According to Schedule 3Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints 2Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints 3Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints 4Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints 5Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints 6Commonwealth Fund Case Study Points to 'Continuous Innovation' at Group Health Cooperative 2Commonwealth Fund Case Study Points to 'Continuous Innovation' at Group Health Cooperative 3Prism glasses expand the view for patients with hemianopia 19103 1Prism glasses expand the view for patients with hemianopia 19103 2Prism glasses expand the view for patients with hemianopia 19103 3Aon Study Finds Stability in Nationwide Liability Costs in the Long Term Health Care Sector 19100 1Aon Study Finds Stability in Nationwide Liability Costs in the Long Term Health Care Sector 19100 2Aon Study Finds Stability in Nationwide Liability Costs in the Long Term Health Care Sector 19100 3Hospital Association Moves Headquarters to Downtown Austin 19097 1Hospital Association Moves Headquarters to Downtown Austin 19097 2Independence Blue Cross Supports 2008 Senior Games 19094 1Independence Blue Cross Supports 2008 Senior Games 19094 2
...SS WIRE)--Apr 14, 2007 - In a late-breaker,present...ssociation,for the Study of the Liver (EASL), rese...m analysis of the PROVE 1 clinical trial,which is...y with,the investigational hepatitis C protease in...th pegylated interferon (peg-IFN) and,ribavirin (R...
...ted Phase 2 Study Now Underway at Nine,Centers, SA...regene,Inc., a biopharmaceutical company, today p...linical trial of CERE-120, a gene,therapy product ...sease, demonstrating a 36 percent (p<0.001) reduct...inistration, as measured,by the Unified Parkinson,...
Other Medicine Technology:Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 2Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 3Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 4Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 5Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 6Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 7Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 8Ceregene Presents Long Term Follow-Up Data From Phase 1 Trial of,CERE-120 Demonstrating Improved Motor Function in Parkinson's,Patients 2Ceregene Presents Long Term Follow-Up Data From Phase 1 Trial of,CERE-120 Demonstrating Improved Motor Function in Parkinson's,Patients 3Ceregene Presents Long Term Follow-Up Data From Phase 1 Trial of,CERE-120 Demonstrating Improved Motor Function in Parkinson's,Patients 4
The dual lumen M.R.I. model is available with 1.0 or 1.2 mm inner diameter catheters (each lumen). ,Dual oval lumen catheters offer larger lumen equivalency while maintaining maximum catheter strengt
The standard-sized titanium port may be ordered with a silicone or polyurethane catheter. The silicone catheter is available with inner diameter sizes of 0.9, 1.0, 1.4, 1.6 mm. The polyurethane cathe
...nect to the CoolGard 3000 Thermal Regulation Syste...re input by the user. It remotely senses changes i...ts the temperature of the circulating saline withi...enance of temperature. The CoolGard 3000 represent...
Used for vascular access. Supplied sterile in peel-open packages. Intended for one-time use.
Medicine Products: